Share

|

|

|

Add-on telitacicept improves clinical response in patients with active SLE

Telitacicept used in addition to standard therapy shows promising efficacy in Chinese patients with active systemic lupus erythematosus, suggests a phase 2b trial published in the Annals of the Rheumatic Diseases.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Respiratory infection risk heightened in primary Sjögren’s syndrome and ILD

Patients with primary Sjögren’s syndrome and interstitial lung disease are at increased risk of respiratory infections, particularly bacterial infections, suggests a study published in Clinical Rheumatology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Remibrutinib shows promise for Sjögren’s syndrome treatment

The Bruton’s tyrosine kinase inhibitor remibrutinib reduces disease activity in patients with Sjögren’s syndrome, show results from the phase 2 LOUiSSE trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Diffusing capacity of lung for carbon monoxide predicts SLE disease severity

The diffusing capacity of the lungs for carbon monoxide could be a surrogate marker for overall disease severity in patients with systemic lupus erythematosus, suggest researchers in Rheumatology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Complete remission best for tapering SLE treatment

To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Add-on tofacitinib shows treatment promise in SSc-ILD

The addition of tofacitinib to conventional disease-modifying antirheumatic drugs could help alleviate sclerosis in patients with systemic sclerosis-associated interstitial lung disease, suggests research.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Autoantibodies may identify Sjögren’s syndrome in Ro-negative patients

The use of autoantibody biomarkers could be a feasible way of identifying Sjögren’s syndrome in patients lacking the anti-Ro antibody without the need for a salivary gland lip biopsy, suggests a proof-of-concept study.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Serious infection risk not increased by rituximab and belimumab in SLE

Neither rituximab nor belimumab significantly increase the risk for serious infection in patients with systemic lupus erythematosus compared with the standard of care, researchers report.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Baricitinib disappoints in SLE-BRAVE trials

Baricitinib has achieved largely negative results in the SLE-BRAVE trials, published in The Lancet.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Reflux symptoms predict interstitial lung disease progression in SSc

Post-hoc analysis of a randomised trial shows that the severity of reflux symptoms in patients with systemic sclerosis predicts radiographic progression of interstitial lung disease.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.